UB CTSI Receives $28.4 Million in Renewed Funding from NIH

Dear friends,

I am thrilled to announce that the University at Buffalo has once again been awarded the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA). The purpose of the CTSAs, awarded to only 63 institutions nationwide, is to speed the translation of research discoveries into improved care for all while prioritizing the needs of the most vulnerable members in the community.

This seven-year, $28.4 million award will allow UB to continue and expand its efforts to improve health outcomes in Western New York and beyond. Today’s announcement brings total CTSA funding since 2015 to UB to just over $65 million.

Our newest CTSA grant builds on the strong foundation laid by our previous awards in 2015 and 2020. This renewed funding will empower UB researchers to continue their critical work, addressing the most pressing health challenges, advancing medical breakthroughs from bench to bedside, and ultimately improving the lives of people in Western New York, across the state and around the world.

Receiving this significant award places UB within a distinguished network of leading institutions across the country, aligning with its goal to become a Top 25 public research university. The UB Clinical and Translational Science Institute (CTSI) brings together the university’s health sciences schools (medicine and biomedical sciences, dental medicine, nursing, pharmacy and pharmaceutical sciences, public health and health professions, and social work) together with UBMD Physicians’ Group, Roswell Park Comprehensive Cancer Center, Kaleida and ECMC, as well as vital community partners and collaborating institutions, which comprise the Buffalo Translational Consortium.

Since its establishment, the CTSA has been instrumental in advancing health research, fostering collaborations and improving health outcomes. It has enabled us to build a strong CTSI that has had a transformative impact on our community. These initiatives have collectively contributed to significant advancements in health care, biomedical research, and public health.

Thank you to Timothy Murphy, MD, principal investigator on the grant, and his outstanding team of writers and researchers. Their commitment to engaging all key regional organizations and amplifying the voices of those most impacted by social determinants of health has been essential in driving positive change.

I am excited about the future of the CTSI and the opportunities it presents for our faculty, staff, residents and students. With continued support, we will continue to be a leader in clinical and translational science and make a substantial contribution to improving health outcomes for our community.

Sincerely, 
 

Allison Brashear, MD, MBA
Dean, Jacobs School of Medicine and Biomedical Sciences
Vice President for Health Sciences
President and CEO, UBMD Physicians' Group